Sökning: "GBM cells"
Visar resultat 1 - 5 av 52 avhandlingar innehållade orden GBM cells.
1. Development of adenoviral vectors for monitoring telomerase activity in living cells
Sammanfattning : ABSTRACT Telomerase activity is a potential molecular marker for cancer and primitive cells in regenerative tissues. The most commonly used method to measure telomerase activity in cells is the telomerase reverse amplification protocol (TRAP) assay, where the protein extracts derived from homogenized cells are analysed. LÄS MER
2. Modeling glioblastoma heterogeneity to decipher its biology
Sammanfattning : Glioblastoma multiforme (GBM) is the most common and lethal form of primary brain tumor that mainly affects adults. GBM displays remarkable intra- and inter-tumoral heterogeneity and contains a subpopulation of cells named glioma stem cells that is believed to be responsible for tumor maintenance, progression and recurrence. LÄS MER
3. New Molecular Approaches to Glioblastoma Therapy
Sammanfattning : Glioblastoma (GBM) is the most common high-grade brain tumor diagnosed in patients who are more than 50 years of age. The standard of care treatment is surgery, followed by radiotherapy and chemotherapy. The median life expectancy of patients is only between 12 to 15 months after receiving current treatment regimes. LÄS MER
4. A Novel Approach for Radiotherapy and Radiosurgery Treatment Planning Accounting for High-Grade Glioma Invasiveness into Normal Tissue
Sammanfattning : High-grade gliomas (HGGs) are a type of malignant brain cancer, which include glioblastomas (GBMs). In adults, GBM is the most common malignant primary brain cancer. Attempts to treat patients with GBMs have been conducted for over a century, but the prognosis has only marginally improved. LÄS MER
5. Synergistic effects of mesenchymal stromal cells and immunotherapy in experimental brain tumors
Sammanfattning : Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain tumor. In spite of surgical resection, combined radiation therapy and chemotherapy, the mean survival is less than 15 months following diagnosis. LÄS MER
